Olezarsen decreased levels of triglycerides compared with placebo in patients with moderate hypertriglyceridemia and elevated cardiovascular risk, according to a late-breaking trial presented in a Hot Line session today at ESC Congress 2025 and simultaneously published in New England Journal of Medicine.